Showing 1 - 20 results of 1,457 for search '(( 50 ns decrease ) OR ((((( _ we decrease ) OR ( _ eu decrease ))) OR ( 10 i decrease ))))*', query time: 0.18s Refine Results
  1. 1

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit Masania (7164239)

    Published 2023
    “…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
  2. 2

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit, Masania

    Published 2023
    “…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
    Get full text
    Get full text
    Get full text
    article
  3. 3

    Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…</p><p dir="ltr">Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex: Frontiers in Molecular Biosciences: <a href="https://dx.doi.org/10.3389/fmolb.2022.1018464" rel="noreferrer" target="_blank">https://dx.doi.org/10.3389/fmolb.2022.1018464</a>, published online 19 October 2022.…”
  4. 4

    Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…<p dir="ltr">Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex: Frontiers in Molecular Biosciences <a href="https://dx.doi.org/10.3389/fmolb.2022.846996" target="_blank">https://dx.doi.org/10.3389/fmolb.2022.846996</a>, published online 22 July 2022.…”
  5. 5
  6. 6

    The trans-10, cis-12 isomer of conjugated linoleic acid decreases adiponectin assembly by PPARγ-dependent and PPARγ-independent mechanisms by Miller, Jessica R.

    Published 2008
    “…The aim of this study was to determine whether the effects of t-10, c-12 CLA on adiponectin and TG are mediated through modulation of the transcription factor peroxisome proliferator-activated receptor γ (PPARγ). 3T3-L1 cells were treated either during or after differentiation into adipocytes with 100 μM t-10, c-12 CLA with or without 10 μM troglitazone, a PPARγ agonist, or 1 μM GW9662, a PPARγ antagonist, and adiponectin and TG levels were analyzed. …”
    Get full text
    article
  7. 7
  8. 8
  9. 9

    A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity by Wesam S. Ahmed (10170053)

    Published 2024
    “…However, questions related to its mechanism of interaction with the substrate, furimazine, as well as bioluminescence activity remain elusive. Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable <u>bioluminescence </u>activity of NLuc in living cells and in vitro. …”
  10. 10
  11. 11

    Notch Signaling Inhibition by LY411575 Attenuates Osteoblast Differentiation and Decreased Ectopic Bone Formation Capacity of Human Skeletal (Mesenchymal) Stem Cells by Nihal AlMuraikhi (6002234)

    Published 2019
    “…Among the affected signaling networks were TGFβ1, SPP1, and ERK regulatory networks. Conclusions. …”
  12. 12
  13. 13
  14. 14
  15. 15

    Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on β-Adrenergic cAMP Signals by Abi-Gerges, Aniella

    Published 2009
    “…Regulation of β-adrenergic cAMP signals by PDEs was blunted in hypertrophied myocytes, as demonstrated by the diminished effects of IBMX (100 μmol/L) and of both the PDE3 inhibitor cilostamide (1 μmol/L) and the PDE4 inhibitor Ro 201724 (10 μmol/L). …”
    Get full text
    Get full text
    Get full text
    Get full text
    article
  16. 16

    The Anti-Tumor Agent Sodium Selenate Decreases Methylated PP2A, Increases GSK3βY216 Phosphorylation, Including Tau Disease Epitopes and Reduces Neuronal Excitability in SHSY-5Y Neu... by Wesal Habbab (17346961)

    Published 2019
    “…PP2A, GSK3β and Tau reside together in a complex, which facilitates their interaction and (dys)-function as has been reported for several neurological disorders. In this study we recorded maximum increase in total PP2A at 3 µM sodium selenate in a neuron cell line. …”
  17. 17

    10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes by Goran Petrovski (129836)

    Published 2020
    “…<h3>Aim</h3><p dir="ltr">The aim of this study was to evaluate the 10-day initiation protocol for MiniMed 670G hybrid closed-loop (HCL) system in individuals with type 1 diabetes on multiple daily injection (MDI) in achieving desirable glycemic control.…”
  18. 18

    Theoretical and experimental insights into the C-steel aqueous corrosion inhibition at elevated temperatures in 1.0 M HCl via multi-carbonyl Gemini cationic surfactants by Nasser M. El-Basiony (18021631)

    Published 2023
    “…In this study, our goal was to prepare two amido Gemini cationic surfactants, LAPG and MAPG, each with different alkyl chains and multiple carbonyl groups as rich electronic rich centers. We aimed to evaluate these surfactants as potential corrosion inhibitors for carbon steel (CS) in 1 M HCl at temperatures of 25–55 ± 0.1 °C. …”
  19. 19
  20. 20

    LDL-C Targets in Secondary Prevention: How Low Should We Go? by Karim Bayoumy (3496688)

    Published 2019
    “…<h3>Abstract</h3><p dir="ltr">The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. …”